57 related articles for article (PubMed ID: 9627663)
1. Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC.
Pan X; Caillon A; Fan S; Khan S; Tomatsu S; Pshezhetsky AV
Cells; 2024 May; 13(10):. PubMed ID: 38786099
[TBL] [Abstract][Full Text] [Related]
2. Mucopolysaccharidosis.
Bhakthaganesh K; Manumuraleekrishna ; Vanathi M; Ahmed S; Gupta N; Tandon R
Taiwan J Ophthalmol; 2023; 13(4):443-450. PubMed ID: 38249505
[TBL] [Abstract][Full Text] [Related]
3. Management of Corneal Clouding in Patients with Mucopolysaccharidosis.
McGrath O; Au L; Ashworth J
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362047
[TBL] [Abstract][Full Text] [Related]
4. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
[TBL] [Abstract][Full Text] [Related]
5. Multimodal imaging of Hurler syndrome-related keratopathy treated with deep anterior lamellar keratoplasty.
Da Cunha E; Georgeon C; Bouheraoua N; Putterman M; Brignole-Baudouin F; Borderie VM
BMC Ophthalmol; 2020 Oct; 20(1):433. PubMed ID: 33129306
[TBL] [Abstract][Full Text] [Related]
6. Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases.
Bastola P; Song L; Gilger BC; Hirsch ML
Pharmaceutics; 2020 Aug; 12(8):. PubMed ID: 32823625
[TBL] [Abstract][Full Text] [Related]
7. Hurdles in treating Hurler disease: potential routes to achieve a "real" cure.
van den Broek BTA; van Doorn J; Hegeman CV; Nierkens S; Lindemans CA; Verhoeven-Duif N; Boelens JJ; van Hasselt PM
Blood Adv; 2020 Jun; 4(12):2837-2849. PubMed ID: 32574368
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmological Findings in Mucopolysaccharidoses.
Tomatsu S; Pitz S; Hampel U
J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31540112
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
Orphanet J Rare Dis; 2019 May; 14(1):118. PubMed ID: 31142378
[TBL] [Abstract][Full Text] [Related]
10. A novel explanation of corneal clouding in a bone marrow transplant-treated patient with Hurler syndrome.
Yuan C; Bothun ED; Hardten DR; Tolar J; McLoon LK
Exp Eye Res; 2016 Jul; 148():83-89. PubMed ID: 27235795
[TBL] [Abstract][Full Text] [Related]
11. AAV Gene Therapy for MPS1-associated Corneal Blindness.
Vance M; Llanga T; Bennett W; Woodard K; Murlidharan G; Chungfat N; Asokan A; Gilger B; Kurtzberg J; Samulski RJ; Hirsch ML
Sci Rep; 2016 Feb; 6():22131. PubMed ID: 26899286
[TBL] [Abstract][Full Text] [Related]
12. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses.
Fenzl CR; Teramoto K; Moshirfar M
Clin Ophthalmol; 2015; 9():1633-44. PubMed ID: 26379420
[TBL] [Abstract][Full Text] [Related]
13. Anterior segment OCT imaging in mucopolysaccharidoses type I, II, and VI.
Ahmed TY; Turnbull AM; Attridge NF; Biswas S; Lloyd IC; Au L; Ashworth JL
Eye (Lond); 2014 Mar; 28(3):327-36. PubMed ID: 24384963
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Ultrasound Findings in Infants with Severe (Hurler Phenotype) Untreated Mucopolysaccharidosis (MPS) Type I.
Schroeder L; Orchard P; Whitley CB; Berry JM; Tolar J; Miller W; Braunlin EA
JIMD Rep; 2013; 10():87-94. PubMed ID: 23430808
[TBL] [Abstract][Full Text] [Related]
15. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?
Pitz S; Ogun O; Arash L; Miebach E; Beck M
Graefes Arch Clin Exp Ophthalmol; 2009 Jul; 247(7):975-80. PubMed ID: 19159944
[TBL] [Abstract][Full Text] [Related]
16. Negative ERGs in mucopolysaccharidoses (MPS) Hurler-Scheie (I-H/S) and Hurler (I-H)-syndromes.
Tzetzi D; Hamilton R; Robinson PH; Dutton GN
Doc Ophthalmol; 2007 May; 114(3):153-8. PubMed ID: 17464575
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.
Ponder KP; Melniczek JR; Xu L; Weil MA; O'Malley TM; O'Donnell PA; Knox VW; Aguirre GD; Mazrier H; Ellinwood NM; Sleeper M; Maguire AM; Volk SW; Mango RL; Zweigle J; Wolfe JH; Haskins ME
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13102-7. PubMed ID: 12232044
[TBL] [Abstract][Full Text] [Related]
18. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up.
Gullingsrud EO; Krivit W; Summers CG
Ophthalmology; 1998 Jun; 105(6):1099-105. PubMed ID: 9627663
[TBL] [Abstract][Full Text] [Related]
19. The ocular features of the mucopolysaccharidoses.
Ashworth JL; Biswas S; Wraith E; Lloyd IC
Eye (Lond); 2006 May; 20(5):553-63. PubMed ID: 15905869
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
